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Background: CT enterography yields striking findings in the
bowel wall in Crohn’s disease. These images may help to evaluate
whether small bowel narrowing results from active disease requiring
anti-inflammatory therapy. However, the clinical relevance of these
images is unknown. It is also not known if these radiologic findings
correlate with objective biomarkers of inflammation.
Methods: In a blinded and independent evaluation, IBD subspe-
cialty gastroenterologists reviewed clinical data, and CT radiologists
reviewed CT enterography scans of 67 consecutive patients with
Crohn’s disease and suspicion of either small bowel inflammation or
stricture. Comparisons were made between (1) clinical and radio-
logic assessments of inflammation and stricture, (2) clinical assess-
ments before and after computed tomographic enterography (CTE)
reports were revealed, and (3) radiologic findings and objective
biomarkers of inflammation.
Results: (1) Individual CTE findings correlated poorly (Spear-
man’s rho  0.30) with clinical assessment; (2) clinicians did not
suspect 16% of radiologic strictures, and more than half the cases of
clinically suspected strictures did not have them on CTE; (3) CTE
data changed clinicians’ perceptions of the likelihood of steroid
benefit in 41 of 67 cases; (4) specific CTE findings correlated with
CRP, and a distinct set of CTE findings correlated with ESR in the
subset of patients who had these biomarkers measured.
Conclusions: CTE seems to add unique information to clinical
assessment, both in detecting additional strictures and in changing
clinicians’ perceptions of the likelihood of steroids benefiting pa-
tients. The biomarker correlations suggest that CTE is measuring
real biologic phenomena that correlate with inflammation, providing
information distinct from that in a standard clinical assessment.
(Inflamm Bowel Dis 2007;13:262–268)
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C rohn’s disease of the small intestine is frequently man-ifested by abdominal pain. However, it is often not clear,
despite careful clinical evaluation, whether this pain is caused
by inflammation, by stenosis and upstream dilation, or by a
combination of inflammation and stricture. Ideally, diagnostic
assessment could differentiate which process is predominant,
and therapy could be directed at either inflammation (e.g.,
steroids, infliximab) or stricture (e.g., dilation, strictureplasty,
or resection). Small bowel follow-through can define the
extent and severity of narrowing, but it provides little data on
whether narrowing results from inflammation of the wall of
the intestine. Similarly, endoscopy only assesses the superfi-
cial mucosa and does not evaluate the transmural inflamma-
tion in Crohn’s disease. A diagnostic tool that allows imaging
of the entire wall may add additional clinical information and
enable physicians to make more informed treatment decisions
for their patients with Crohn’s disease and abdominal pain.
Computed tomographic enterography (CTE) has been
recently applied to the study of Crohn’s disease. This rapid,
high-resolution scan captures far more detail than a standard
CT and has revealed new findings of unknown significance in
Crohn’s disease. By using low-density “negative” oral con-
trast and 1.25-mm slices, more information can be obtained
from the bowel wall. Wold et al demonstrated that this
method was feasible and tolerated by patients and did not
miss fistulas in 23 cases.1 A study by Guidi et al of 35 patients
with Crohn’s disease showed a positive correlation between
activity seen on CTE and CDAI of more than 150 (active
disease) and a correlation between an elevated ESR and the
presence of fistulas.2
The inflammatory markers erythrocyte sedimentation
rate (ESR) and C-reactive protein (CRP) are not well under-
stood in Crohn’s disease despite their frequent use. Neither
ESR nor CRP is consistently elevated in active disease, yet
both are correlated with disease activity. In addition, they do
not always correlate with each other. Guidi’s data suggest
that ESR may correlate with the breaching of the bowel wall
by the disease process. Other studies3 have suggested that
elevated CRP correlates with responsiveness to medications
that reduce leukocyte attachment to blood vessel endothe-
lium.
Although CTE produces remarkable images, we do not
know whether the information gained adds to clinical deci-
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sion making, or if we are simply spending valuable health
care dollars for very nice pictures. We do not know if CTE is
able to detect unsuspected strictures or to affect management
in meaningful ways. We do not know if CTE correlates with
objective biomarkers of inflammation like ESR and CRP.
Therefore, we designed a retrospective, blinded evaluation
study to test the following hypotheses:
1. CTE findings correlate well with clinical ratings of inflam-
mation (r  0.7);
2. CTE detects additional strictures beyond those suspected
by clinicians;
3. CTE results lead to changes in the clinical likelihood of
benefit from steroids; and
4. CTE findings correlate (r  0) with objective laboratory
markers of inflammation (ESR, CRP).
MATERIALS AND METHODS
Study Design
The study design is presented diagrammatically in Fig-
ure 1. To summarize, retrospective independent evaluations
of anonymized clinical information were performed by IBD
subspecialists (P.H. and E.M.Z.) blinded to the CTE findings,
and retrospective independent evaluations of the CT enterog-
raphy scans were performed by 2 CT radiologists (J.F.P. and
L.P.S.) blinded to the clinical information. Both the clinical
and radiologic evaluators reached consensus on the ratings,
which were used in all statistical analyses. Repeat evaluations
were done by the clinical evaluators after the CTE reports
were revealed. Biomarkers (C-reactive protein, Westergren
erythrocyte sedimentation rate) were recorded if measured in
the 2 weeks before CTE. Statistical comparisons of (1) clin-
ical rating of inflammation with radiologic rating of severity,
(2) clinical rating of stricture likelihood with radiologic pres-
ence of stricture, (3) clinical rating of likelihood of steroid
response before CTE reports were revealed to clinicians with
that after CTE reports were revealed to clinicians, and (4)
CTE radiologic findings with biomarkers were performed.
Examples of these radiologic findings in Figure 2.
Patient Population
Sixty-seven consecutive patients with Crohn’s disease
and a suspicion of small bowel narrowing or inflammation on
their requisition for a CTE (abdominal pain, vomiting, or
some other stated reason for concern for small intestinal
stricture or inflammation) were selected for retrospective
evaluation. CTEs were obtained between October 2002 and
March 2004. One patient appeared twice in the dataset be-
cause of a second CTE performed for clinical reasons during
the review period.
Clinical Evaluation
The IBD subspecialist clinicians (blinded to CTE re-
sults) evaluated all 67 subjects based on anonymized packets
of clinical data from the 6 months before CTE, which in-
cluded (if available): clinic notes, hospital notes, laboratory
tests, endoscopy reports, pathology reports, and small bowel
follow-through reports. The evaluations included (1) a rating
of inflammation on a scale of 0 to 3 (none, mild, moderate,
severe), (2) a rating of the likelihood of the presence of a
clinically significant stricture on a scale of 1 to 5 (very
unlikely, unlikely, not sure, likely, very likely), and (3) a
rating of the likelihood of clinical response to steroids on a
scale of 1 to 5 (very unlikely, unlikely, not sure, likely, very
likely). Consensus ratings were reached and recorded, and
FIGURE 1. Study design. The subjects were evaluated indepen-
dently by IBD subspecialty physicians blinded to the CTE find-
ings and by CT radiologists blinded to the clinical findings. The
IBD subspecialists reviewed anonymized packets of clinical in-
formation, including clinic notes, hospital notes, laboratory
tests, endoscopy reports, pathology reports, and small bowel
follow-through reports, if available, from the 6 months before
the CT enterography date. The clinicians then independently
rated the overall severity of inflammation (0 –3), likelihood of
stricture (1–5), and likelihood of response to steroids (1–5).
Then the 2 clinicians came to a consensus to produce a single
rating for statistical analysis. Then the results of the CTE report
were revealed to the clinicians, and the 3 ratings of overall se-
verity of inflammation, likelihood of stricture, and likelihood of
response to steroid were repeated. Independently, the CT radi-
ologists, blinded to the clinical data, rated 6 items in the images
of the terminal ileum on a severity scale of 0 to 3 (none, mild,
moderate, severe): mucosal enhancement, bowel vascularity,
bowel wall thickening, fat stranding, local fluid (edema), and
bowel fat. A global rating of severity on a scale of 0 to 3 was also
recorded. In addition, possible strictures were measured, and
the most narrow lumen diameter in millimeters and the proxi-
mal bowel diameter (at greatest dilation) in millimeters were
recorded. For purposes of this study, a true stricture was de-
fined as a luminal narrowing to less than 6 mm in the ileum with
proximal dilation to 3 times the diameter of the narrowing. Four
comparisons were made: (1) between the ratings of the clini-
cian and the radiologist on inflammation and global severity, (2)
between the clinicians’ prediction of strictures and the radio-
logic presence of strictures, (3) between the clinicians’ ratings
before and after CTE data were revealed, and (4) between the
radiologic findings and biomarkers of inflammation (Wester-
gren erythrocyte sedimentation rate, C-reactive protein).
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then CTE reports were revealed. Ratings were repeated inde-
pendently, and post-CTE consensus ratings were reached.
Radiologic Evaluation
The 2 CT radiologists independently evaluated 58 of
the CTE scans while blinded to the clinical data, including
determining if luminal narrowing was present. If such nar-
rowing were found, each radiologist independently measured
the smallest diameter and the largest proximal dilation, both
in millimeters. Consensus was reached on each measurement,
and a narrowing was only considered a true radiologic stric-
ture if both the luminal diameter was less than 6 mm and the
proximal dilation was at least 3 times the diameter of the
smallest luminal narrowing.
For 47 of the CTE scans, independent ratings of indi-
vidual findings were made on a scale of 0 to 3 (none, mild,
moderate, severe). The findings recorded were mucosal vas-
cularity, bowel wall thickening, mucosal enhancement, local-
ized fluid (edema), extraluminal gas, fat stranding, bowel fat,
fat proliferation, lymphadenopathy, feces sign, fistulas, and a
global assessment. Consensus ratings were reached and re-
corded for each finding.
Biomarker Data
As this was a retrospective study, it was only spo-
radically that these assays had been performed within 2
weeks of the date of the CTE. As (1) the choice to perform
these assays may not have been random, and (2) these
assays were performed in only a small number of our 51
subjects, we evaluated correlations of radiologic findings
with these biomarkers as an exploratory, hypothesis-gen-
erating endpoint.
Ethical Considerations
Institutional review board approval for this retro-
spective review of data already collected for clinical rea-
sons was obtained (IRB no. 2003-0306). As it was imprac-
ticable to contact and obtain consent from all 67 patients to
review data retrospectively, a waiver of the requirement
for informed consent was approved by the institutional
review board.
Statistical Methods
SAS 9.1 (Cary, NC) was used for the statistical analysis
of the correlation between clinical assessment of inflamma-
tion and CTE findings, with Spearman’s rho calculated for
each pairwise correlation and an alternative hypothesis of rho
 0. The same statistical approach was used for the correla-
tions between CTE findings and biomarkers (CRP and ESR).
A kappa statistic with a 95% confidence interval was calcu-
lated for the agreement between clinically suspected stric-
tures (likelihood  likely or very likely) and radiographically
defined strictures. A change in the likelihood of steroid ben-
efit was defined as a change of at least 1 unit on a likelihood
scale of 1 to 5, and simple proportions and percentages were
calculated for the frequency of changes in this likelihood after
CTE reports were revealed.
RESULTS
CTE Findings Are Not Equivalent to Clinical
Assessment
We initially tried to determine whether CTE was
merely replicating and reinforcing the clinical impression.
If CTE measures the same information, then it is not likely
to contribute significantly to clinical decision making. We
found that the CTE findings of mucosal enhancement,
mucosal vascularity, bowel wall thickening, fat stranding,
localized fluid (edema), bowel fat, fat proliferation, ex-
traluminal gas, lymphadenopathy, fistulas, feces sign, and
the radiologists’ global assessment all correlated poorly
with the clinicians’ ratings of inflammation (Table 1). No
individual finding had a correlation greater than 0.30
(Spearman’s rho). We attempted to use multiple regression
modeling to combine these radiologic ratings and predict
the clinical rating of inflammation and could predict no
more than 27% of the variance in clinical ratings with the
best model.
FIGURE 2. Typical findings of CT enterography in Crohn’s dis-
ease. These images illustrate the findings identified by the 2
radiologists reviewing the CTEs, including: (A) mucosal en-
hancement, recognized by the bright density arising from the
bowel mucosa surrounded by the bowel wall; (B) increased
mesenteric vascularity, recognized by the engorged vascula-
ture associated with the abnormal bowel; (C) bowel wall thick-
ening, recognized by the thickened bowel, wall which normally
measures less than 3 mm thick (the bowel wall is the same den-
sity as the pelvic musculature); (D) extraluminal fluid, recog-
nized by extraluminal fluid (outside the bowel loops) sur-
rounded by an irregular wall and mesenteric stranding; (E)
mesenteric stranding, recognized by ill-defined haziness in the
mesentery, which has a brighter density than mesenteric fat; (F)
extraluminal gas, recognized by very low-density foci outside
the bowel loops (gas is lower density than fluid); (G) fatty prolif-
eration, recognized by prominent fat displacing bowel loops
toward the periphery of the abdomen (fat is lower density than
fluid and mesenteric stranding); (H) lymph node enlargement,
recognized by the abnormal soft-tissue masses in the mesen-
tery, measuring at least 1 cm; (I) feces sign, recognized by in-
traluminal solid material intermixed with gas in the small bowel
(normally seen in the colon and rectum, but when seen within a
loop of small bowel suggests poor transit time through the in-
volved bowel segment); and (J) bowel fat, recognized by the
crescentic low attenuation in the bowel wall, indicating fat (un-
like mesenteric fat, this finding is adjacent to the bowel mucosa
and is confined to the bowel wall).
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FIGURE 2
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Clinicians Suspect Most True Strictures, But Suspect
Many More
We then assessed whether clinicians suspected most or
all of the CTE-identified true strictures. By requiring up-
stream dilation to be at least 3 times the minimum luminal
stricture diameter on the CTE, we used a strict endpoint for
stricture as our gold standard. Strictures clinically identified
as either “possible” or “likely” were defined as clinical sus-
picion of stricture. According to this definition, the clinicians
suspected 84% (16 of 19) of the CTE-identified strictures.
However, the clinicians’ suspicion of stricture was not very
specific, as 17 of 33 subjects in whom strictures were sus-
pected did not have them by these criteria. We found that the
overall agreement between clinicians’ assessment and the
CTE-identified true strictures was poor, with a kappa of 0.34
(95% CI 0.13–0.55; Table 2). CTE was able to identify an
additional 3 unsuspected strictures and was able to demon-
strate there was not a radiologically significant stricture in
more than half the subjects with suspected strictures in this
study sample.
CTE May Change Steroid Use
We then simulated a clinical situation, in which
clinicians made their assessment of the patient’s likelihood
of response to steroids based on available clinical data, and
then revealed the findings of the CTE. We then determined
whether the CTE findings changed the clinicians’ per-
ceived likelihood of steroid benefit for the patient. We
found the CTE findings changed the perceived likelihood
of steroid benefit in 41 of 67 cases (61%) (Table 3). This
was not unidirectional. After the CTE information was
revealed, steroids were rated more likely to help in 18
cases, and less likely to help in 23 cases. In 9 cases, the
rating changed at 2 levels on the 5-point likelihood scale,
5 with increased likelihood of steroid benefit, and 4 with
decreased likelihood.
CTE Findings Correlate with Objective Biomarkers
In an exploratory data analysis, we looked at the cases
in which either a CRP or ESR was drawn within 2 weeks of
the CTE scan. A limited number of subjects had timely
biomarkers available (CRP: N  9; ESR: N  27), and they
were not a random selection, so this analysis can only be used
to generate hypotheses for future, more definitive studies. We
found that mucosal vascularity and global enhancement cor-
related with CRP and that extraluminal findings (extraluminal
gas, localized fluid) seemed to correlate with ESR (Table 4).
Several findings were negatively correlated with ESR, includ-
ing fat proliferation, feces sign, mucosal enhancement, and
bowel wall thickening.
DISCUSSION
We found that CTE identifies findings clearly different
from, and perhaps complementary to, those identified through
clinical assessment. CTE seems to add useful information
about stricture detection and changes simulated clinical de-
TABLE 1. Spearman Correlation between CTE Findings and







Bowel wall thickening 0.09








Radiologists’ global assessment 0.16
*Pearson’s rho with clinical inflammation ratings of none, mild, moderate, or
severe (0–3).
TABLE 2. Agreement between Clinician Assessment of
Likelihood of Strictures and Presence of Radiologic Strictures
(n  58)
Clinical likelihood of stricture
Radiologic stricture
Present Absent
Very unlikely or unlikely 22 33
Not sure, likely, or very likely 17 16
Kappa  0.34 (95% CI: 0.13–0.55).
TABLE 3. Effect of CTE Findings on Clinicians’ Perceived







likely Not sure Likely
Very unlikely 7 4 4 0
Not likely 15 7 7 1
Not sure 3 3 7 2
Likely 0 1 1 5
Weighted kappa  0.32 (95% CI: 0.14–0.49).
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cision making about steroid use. Thus, CTE seems to be a
useful tool in the evaluation of patients with Crohn’s disease
and abdominal pain.
Patients with Crohn’s frequently develop abdominal
pain as a result of bowel narrowing. Commonly used imaging
modalities such as SBFT identify narrowing but do not dem-
onstrate whether the narrowing is due to inflammation and
tissue edema or whether it is fibrotic. Clinical response to an
empiric trial of potent anti-inflammatory therapy including
steroids or infliximab is often used to provide a clue about the
nature of the narrowing. As Crohn’s is a transmural disease,
it should not be too surprising that being able to image the full
thickness of the bowel wall adds information to the assess-
ment of these patients. Our finding that CTE does not simply
recapitulate clinical assessment and is able to identify unsus-
pected strictures supports this idea.
Our exploratory analysis of biomarkers that might cor-
relate with CTE found an apparent correlation of CRP with
vascular and intrabowel findings and of ESR with extralumi-
nal findings. These hypotheses need to be tested in larger
prospective studies. If proven, they may provide new insight
as to the meaning and clinical implications of elevated ex-
pression of these markers in Crohn’s patients.
Because CRP has been shown to be elevated in coro-
nary artery disease, it is tempting to speculate that the corre-
lation between CRP and both increased vascularity and mu-
cosal enhancement means the CTE findings are detecting
inflammation at the vascular level. Many studies have con-
nected vascular inflammation and abnormalities in vascular
function to the pathogenesis of inflammatory bowel dis-
ease.4–7 CTE may offer a noninvasive way to detect vascular
abnormalities in Crohn’s disease that was not previously
available. Findings similar to ours, of elevated CRP correlat-
ing with increased vascularity detected on CTE, were ob-
served in a study designed with this correlation as a primary
endpoint.8 However, a different study, which used either
SBFT or CTE to detect radiologic abnormalities in Crohn’s
disease, did not find a correlation with CRP.9 A study by
Guidi et al2 showed that ESR was correlated with fistulas,
similar to our finding of a correlation between extraintestinal
manifestations and ESR, but we had too few fistulas to report
any correlation.
This study had several limitations. Because of the ret-
rospective character of the study, bias in assessment was a
possibility. We minimized this by blinding the radiologists to
the clinical data and blinding the clinicians to the CTE data in
the initial assessment. Also because this was a retrospective
study, we had incomplete data on many patients. Some pa-
tients had not had a recent CRP or small bowel follow-
through. Others had not had a recent endoscopy with biopsy
at the time of CTE. This limitation made the clinical assess-
ment a bit more true to practice, where complete data are
rarely available. However, the clinical assessment also lacked
direct physical assessment, and it is not clear that reading
notes, lab reports, and radiologic reports accurately simulates
clinical assessment in actual practice. The biomarkers we
chose to evaluate have been measured infrequently, so the
correlations found should be conservatively considered as
hypothesis-generating.
From this study we have learned that CTE offers new,
complementary information about symptoms of obstruction
in Crohn’s disease, rather than merely confirming and rein-
forcing the clinical impression. Our finding is supported by
the results of the recent study by Bodily et al, which showed
that quantitative measurement of mural attenuation on CTE
was highly correlated with histologic findings of inflamma-
tion.10 In addition to detecting mucosal inflammation, CTE
seems to be able to detect functionally significant and clini-
cally unsuspected strictures and to rule out significant stric-
tures in many patients in whom they are suspected. The
simulation of clinical decision making about steroid benefits
in the present study suggests CTE may also be able to change
clinical management in this group of patients. However, to
prove the value of CTE in the clinical assessment of Crohn’s
disease, we need prospective studies that can determine
whether the information gained from CTE actually changes
clinical decision making and clinical outcomes. Future re-
search should also address whether vascular findings on CTE
are truly detecting vascular dysfunction and whether ESR is
truly a marker of Crohn’s disease activity extending beyond
the serosa.
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Mucosal enhancement 0.10 0.35
Mucosal vascularity 0.38 0.23
Bowel wall thickening 0.00 0.36
Localized fluid (edema) 0.00 0.22
Fat stranding 0.04 0.06
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Radiologists’ global assessment 0.26 0.26
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